Clearstate Insights Covid-19: point-of-care vs. lab-based testing Covid-19 testing has emerged as a top priority for clinical laboratories and many IVD players. SARS-CoV-2 tests make up more than half of Asia-Pacific’s total infectious disease diagnostics market. Healthcare | Asia | EIU Healthcare | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care diagnostics
Clearstate Insights The Future of Pathology: Four Growth Areas in Tissue Diagnostics (TDx) Healthcare | Global | EIU Healthcare | IVD Gateway | Tissue Diagnostics (TDx)
Clearstate Insights The traditional clinical lab evolves: Three technologies Healthcare | EIU Healthcare | IVD Gateway | Healthcare
Clearstate Insights Covid-19: Three purchasing behaviour trends at molecular labs (Asia-Pacific) Healthcare | EIU Healthcare | IVD Gateway | Healthcare
Gateway Solutions: Data-driven intelligence for the healthcare industryWe identify realistic opportunities and enable growth strategies through current, credible, granular data for the IVD and Surgical sectors. Learn more